IDEXX Laboratories IDXX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
IDEXX Laboratories (IDXX) Business Model and Operations Summary
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
Key Insights
IDEXX Laboratories (IDXX) Core Market Data and Business Metrics
Latest Closing Price
$418.57Market Cap
$33.86 BillionPrice-Earnings Ratio
39.23Total Outstanding Shares
81.04 Million SharesTotal Employees
11,000Dividend
No dividendIPO Date
June 21, 1991SIC Description
In Vitro & In Vivo Diagnostic SubstancesPrimary Exchange
NASDAQHeadquarters
One Idexx Drive, Westbrook, ME, 04092-2041
Historical Stock Splits
If you bought 1 share of IDXX before November 27, 2007, you'd have 4 shares today.
| Execution Date | Split Amount |
|---|---|
| June 16, 2015 | 2-for-1 |
| November 27, 2007 | 2-for-1 |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $929.00 Million |
| Exchange Gains/Losses | $-9.53 Million |
| Net Cash Flow From Financing Activities, Continuing | $-878.07 Million |
| Net Cash Flow, Continuing | $-156.13 Million |
| Net Cash Flow From Investing Activities, Continuing | $-207.06 Million |
| Net Cash Flow | $-165.67 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Diluted Average Shares | $83.25 Million |
| Benefits Costs and Expenses | $2.79 Billion |
| Basic Average Shares | $82.47 Million |
| Income Tax Expense/Benefit | $221.96 Million |
| Provision For Loan, Lease, And Other Losses | $6.87 Million |
| Diluted Earnings Per Share | $10.67 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $865.43 Million |
| Comprehensive Income/Loss Attributable To Parent | $865.43 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $-22.44 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Prepaid Expenses | $58.63 Million |
| Other Non-current Liabilities | $12.41 Million |
| Liabilities | $1.70 Billion |
| Other Current Assets | $959.39 Million |
| Long-term Debt | $617.80 Million |
| Fixed Assets | $713.12 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||